Atyr Pharma Inc
LIFE
Market Cap$131.12M
Close$
$0.12
93.9% downside
Current Fair Value
93.9% downsideOvervalued by 93.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $131.12 Million |
|---|---|
| Enterprise Value | $137.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.84 |
| Beta | 1.19 |
| Outstanding Shares | 90,120,235 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.28 |
|---|---|
| PEG | -36.79 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.96 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Atyr Pharma Inc
80 employees
CEO: Sanjay Shukla atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological ...